Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.87%
#2 0G 0G +29.33%
#3 SAFEcoin SAFEcoin +22.40%
#4 VVS Finance VVS Finance +20.47%
#5 Seeker Seeker +20.05%
#6 Zora Zora +19.92%
#7 Full Moon Full Moon +17.70%
#8 Concordium Concordium +17.06%
#9 Notcoin Notcoin +15.26%
#10 Axelar Axelar +15.23%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Settings
Language
ENGLISH
Currency
USD
Theme
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Rank in Stocks #13174
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Share Price
$8.24
Market Cap
$500.72M
Change (1 day)
-1.60%
Change (1 year)
122.00%
Country
US
Trade Kyverna Therapeutics, Inc. (KYTX)

Category

Healthcare
Revenue for Kyverna Therapeutics, Inc. (KYTX)
Revenue in Aug 2026 TTM: 0
According to Kyverna Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Kyverna Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH